Mohammad Kamal Abdelnasser, Ayat Bakhet, Amal Hosni, Dalia Tarik Kamal, Osama Bakr Osman, Mohammed Anter Abdelhameed, Mohamed Ma Moustafa
{"title":"Alpha defensin immunoassay is more effective for ruling out rather than diagnosing periprosthetic joint infection (PJI): a prospective cohort study.","authors":"Mohammad Kamal Abdelnasser, Ayat Bakhet, Amal Hosni, Dalia Tarik Kamal, Osama Bakr Osman, Mohammed Anter Abdelhameed, Mohamed Ma Moustafa","doi":"10.1186/s42836-025-00337-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accurate and timely diagnosis of periprosthetic joint infection (PJI) is of utmost importance. Although synovial alpha-defensin has shown potential as a biomarker, recent studies have questioned its additional benefit over traditional synovial biomarkers and advised against its routine use. The primary objective is to evaluate the diagnostic accuracy of the alpha-defensin immunoassay in PJI. Secondary objectives include comparing its diagnostic accuracy against traditional biomarkers and assessing our results in the context of existing research to provide a solid perspective on its clinical utility.</p><p><strong>Methods: </strong>This is a prospective cohort study. Synovial samples were obtained at the time of revision arthroplasty or from painful arthroplasties. A complete laboratory workup was performed, including CBC, ESR, CRP, WBCs count. Synovial samples were analyzed for leucocytic count, PMN percentage, leucocyte esterase, and alpha-defensin immunoassay. Culture and sensitivity, and histopathology were also done. Patients who met the inclusion criteria were classified into septic and aseptic according to MSIS criteria.</p><p><strong>Results: </strong>Ninety joints met our inclusion criteria. Alpha-defensin immunoassay was positive in 36 joints and negative in 54 joints, with 1 false positive and 3 false negatives, resulting in a sensitivity of 92.11% (95% CI, 78.62-98.34%), a specificity of 98.08% (95% CI, 89.74-99.95%), positive predictive value (PPV) of 49.43% (95% CI, 12.28-87.22%), negative predictive value (NPV) of 99.84% (95% CI, 99.52-99.94%) and diagnostic accuracy of 97.96% (95% CI, 92.48-99.78%). The optimal cutoff was 9.2, and the area under the curve (AUC) was 0.945.</p><p><strong>Conclusions: </strong>While the alpha defensin immunoassay is not recommended to be used routinely as a screening method for PJI, its high specificity and NPV make it a valuable addition to traditional blood and synovial parameters in the diagnosis of complex hip and knee PJI, particularly for ruling out infection.</p>","PeriodicalId":52831,"journal":{"name":"Arthroplasty","volume":"7 1","pages":"52"},"PeriodicalIF":4.3000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthroplasty","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s42836-025-00337-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Accurate and timely diagnosis of periprosthetic joint infection (PJI) is of utmost importance. Although synovial alpha-defensin has shown potential as a biomarker, recent studies have questioned its additional benefit over traditional synovial biomarkers and advised against its routine use. The primary objective is to evaluate the diagnostic accuracy of the alpha-defensin immunoassay in PJI. Secondary objectives include comparing its diagnostic accuracy against traditional biomarkers and assessing our results in the context of existing research to provide a solid perspective on its clinical utility.
Methods: This is a prospective cohort study. Synovial samples were obtained at the time of revision arthroplasty or from painful arthroplasties. A complete laboratory workup was performed, including CBC, ESR, CRP, WBCs count. Synovial samples were analyzed for leucocytic count, PMN percentage, leucocyte esterase, and alpha-defensin immunoassay. Culture and sensitivity, and histopathology were also done. Patients who met the inclusion criteria were classified into septic and aseptic according to MSIS criteria.
Results: Ninety joints met our inclusion criteria. Alpha-defensin immunoassay was positive in 36 joints and negative in 54 joints, with 1 false positive and 3 false negatives, resulting in a sensitivity of 92.11% (95% CI, 78.62-98.34%), a specificity of 98.08% (95% CI, 89.74-99.95%), positive predictive value (PPV) of 49.43% (95% CI, 12.28-87.22%), negative predictive value (NPV) of 99.84% (95% CI, 99.52-99.94%) and diagnostic accuracy of 97.96% (95% CI, 92.48-99.78%). The optimal cutoff was 9.2, and the area under the curve (AUC) was 0.945.
Conclusions: While the alpha defensin immunoassay is not recommended to be used routinely as a screening method for PJI, its high specificity and NPV make it a valuable addition to traditional blood and synovial parameters in the diagnosis of complex hip and knee PJI, particularly for ruling out infection.